Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
PET-imaging of Two Vartumabs in Patients With Solid Tumors
Details : 89-Zr DFO-N-Suc-F8scFv is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
October 17, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Funding
VAR2 Pharmaceuticals Wins MilliporeSigma’s Advance Biotech Grant
Details : As part of the grant award, VAR2 Pharmaceuticals will receive in-kind MilliporeSigma products and consultation support to advance its harvest, downstream, and formulations process development challenges in the production of its drug-conjugated malaria pr...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 06, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Funding